{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:43Z","timestamp":1793239423951,"version":"4.5.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.neubiorev.2025.106431","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:33:17Z","timestamp":1760884397000},"page":"106431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Novel psychoactive substances (NPS) as a risk factor for psychosis: A systematic review of the literature"],"prefix":"10.1016","volume":"179","author":[{"given":"Alessio","family":"Mosca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Mancusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Miuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Cavallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Martin","family":"Corkery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Di Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pasino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Santovito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Marrangone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Vicinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pettorruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s13181-016-0571-7","article-title":"Acute toxicity associated with use of 5F-Derivations of synthetic cannabinoid receptor agonists with analytical confirmation","volume":"12","author":"Abouchedid","year":"2016","journal-title":"J. Med. Toxicol."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2025.106431_bib2","article-title":"Diagnostic stability over one year in first-episode psychosis","volume":"86","author":"Addington","year":"2006","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib3","doi-asserted-by":"crossref","DOI":"10.4065\/81.4.550","article-title":"Rhabdomyolysis after ingestion of \u2018foxy,\u2019 a hallucinogenic tryptamine derivative","volume":"81","author":"Alatrash","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.neubiorev.2025.106431_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1046486","article-title":"Akathisia after chronic usage of synthetic cathinones: a case study","volume":"13","author":"Albert","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.64719\/pb.4481","article-title":"New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report","volume":"54","author":"Alhassan","year":"2024","journal-title":"Psychopharmacol Bull."},{"key":"10.1016\/j.neubiorev.2025.106431_bib6","doi-asserted-by":"crossref","DOI":"10.2147\/NDT.S107622","article-title":"Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients","volume":"12","author":"Altintas","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/JCP.0000000000001275","article-title":"A 4-Year retrospective analysis of patients presenting at the emergency department with synthetic cannabinoid intoxication in Turkey","volume":"40","author":"Altintop","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106431_bib8","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM) 5th ed.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1016\/j.neubiorev.2025.106431_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209573","article-title":"A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia","author":"Anderson","year":"2015","journal-title":"BMJ Case Rep."},{"issue":"DEC.","key":"10.1016\/j.neubiorev.2025.106431_bib10","article-title":"Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases","volume":"187","author":"Arendt","year":"2005","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib11","article-title":"Acute psychosis following ingestion of \u2018rapture","volume":"12","author":"Austin","year":"2004","journal-title":"Australas. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib12","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1037\/0022-006X.70.5.1129","article-title":"The use of acceptance and commitment therapy to prevent the rehospitalization of psychotic patients: a randomized controlled trial","volume":"70","author":"Bach","year":"2002","journal-title":"J. Consult. Clin. Psychol."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/oxfordjournals.schbul.a007010","article-title":"When does experience of psychosis result in a need for care? A prospective general population study","volume":"29","author":"Bak","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neubiorev.2025.106431_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2017.01.020","article-title":"Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: a case series","volume":"273","author":"Barcel\u00f3","year":"2017","journal-title":"Forensic Sci. Int."},{"issue":"12","key":"10.1016\/j.neubiorev.2025.106431_bib15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1177\/0269881116658990","article-title":"Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis","volume":"30","author":"Bassir Nia","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0000000000000116","article-title":"Case series of 21 synthetic cathinones abuse","volume":"34","author":"Batisse","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/08897077.2011.637610","article-title":"Spice: a new \u2018legal\u2019 herbal mixture abused by young active duty military personnel","volume":"33","author":"Bebarta","year":"2012","journal-title":"Subst. Abus."},{"issue":"9","key":"10.1016\/j.neubiorev.2025.106431_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3109\/15563650.2015.1089576","article-title":"Intoxications involving MDPV in Sweden during 2010\u20132014: results from the STRIDA project","volume":"53","author":"Beck","year":"2015","journal-title":"Clin. Toxicol."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.psym.2011.01.004","article-title":"Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists","volume":"52","author":"Benford","year":"2011","journal-title":"Psychosomatics"},{"issue":"12","key":"10.1016\/j.neubiorev.2025.106431_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015716","article-title":"Characteristics of NPS use in patients admitted to acute psychiatric services in southeast scotland: a retrospective cross-sectional analysis following public health interventions","volume":"7","author":"Bennett","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/08897077.2012.677754","article-title":"Synthetic cannabinoid overdose in a 20-year-old Male US soldier","volume":"34","author":"Berry-Cab\u00e1n","year":"2013","journal-title":"Subst. Abus."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jemermed.2015.06.053","article-title":"Synthetic cannabinoid abuse in adolescents: a case series","volume":"49","author":"Besli","year":"2015","journal-title":"J. Emerg. Med."},{"issue":"12","key":"10.1016\/j.neubiorev.2025.106431_bib23","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1080\/15563650.2021.1909730","article-title":"Acute toxicity from the synthetic cathinone n -ethylpentylone (ephylone) in the United Kingdom","volume":"59","author":"Blanco","year":"2021","journal-title":"Clin. Toxicol."},{"issue":"7","key":"10.1016\/j.neubiorev.2025.106431_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/brainsci8070133","article-title":"Synthetic cannabinoid use in a case series of patients with psychosis presenting to acute psychiatric settings: clinical presentation and management issues","volume":"8","author":"Bonaccorso","year":"2018","journal-title":"Brain Sci."},{"issue":"9","key":"10.1016\/j.neubiorev.2025.106431_bib25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1177\/0269881109102541","article-title":"mCPP: an undesired addition to the ecstasy market","volume":"24","author":"Bossong","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib26","article-title":"Report of five cases of 2,5-dimethoxy-4-(n)-propylphenethylamine (2C-P) intoxication following recreational use","volume":"27","author":"Bretaudeau Deguigne","year":"2015","journal-title":"Toxicol. Anal. Et. Clin."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/papt.12222","article-title":"The digital revolution and its impact on mental health care","volume":"92","author":"Bucci","year":"2019","journal-title":"Psychol. Psychother. Theory Res. Pract."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000390","article-title":"Combined NMDA inhibitor use in a patient with Multisubstance-induced psychotic disorder","volume":"12","author":"Caloro","year":"2018","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.neubiorev.2025.106431_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.addbeh.2016.03.032","article-title":"Use of benzylglycinamide by a HIV-seropositive polysubstance user: the changing pattern of novel psychoactive substance use among youths","volume":"60","author":"Caloro","year":"2016","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neubiorev.2025.106431_bib30","doi-asserted-by":"crossref","unstructured":"Caton, C.L., Drake, R.E., Hasin, D.S., Dominguez, B., Shrout, P.E., Samet, S., & Schanzer, B. (2005). Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses.[Erratum appears in Arch Gen Psychiatry. 2005 May;62(5):493 Note: Schanzer, W Bella [corrected to Schanzer, Bella]]. Archives of General Psychiatry, 62(2).","DOI":"10.1001\/archpsyc.62.5.493"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/15504263.2014.929364","article-title":"Use of synthetic cannabinoids in patients with psychotic disorders: case series","volume":"10","author":"Celofiga","year":"2014","journal-title":"J. Dual Diagn."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s13181-013-0306-y","article-title":"Acute psychosis associated with recreational use of benzofuran 6-(2-Aminopropyl)Benzofuran (6-APB) and cannabis","volume":"9","author":"Chan","year":"2013","journal-title":"J. Med. Toxicol."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2710","article-title":"Methamphetamine-associated psychosis: clinical presentation, biological basis, and treatment options","volume":"34","author":"Chiang","year":"2019","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/ph17040535","article-title":"Investigating the effectiveness of brexpiprazole in subjects with schizophrenia spectrum illness and Co-Occurring substance use disorder: a prospective, multicentric, Real-World study","volume":"17","author":"Chiappini","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.neubiorev.2025.106431_bib35","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.2174\/1570159X19666210113151136","article-title":"The benzydamine experience: a systematic review of benzydamine abuse","volume":"19","author":"Chiappini","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib36","article-title":"New psychoactive substances and suicidality: a systematic review of the current literature","volume":"57","author":"Chiappini","year":"2021","journal-title":"Med. (Kaunas. Lith. )"},{"key":"10.1016\/j.neubiorev.2025.106431_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105691","article-title":"New trends of drug abuse in custodial settings: a systematic review on the misuse of over-the-counter drugs, prescription-only-medications, and new psychoactive substances","volume":"162","author":"Chiappini","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"9","key":"10.1016\/j.neubiorev.2025.106431_bib38","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/0960327121996043","article-title":"Synthetic cathinone poisoning from ingestion of drug-laced \u201cinstant coffee packets\u201d in Taiwan","volume":"40","author":"Chou","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.22543\/2392-7674.1356","article-title":"Psychological and psychiatric characterization of various groups of drugs users","volume":"9","author":"Ciuc\u0103 Anghel","year":"2022","journal-title":"J. Mind Med. Sci."},{"key":"10.1016\/j.neubiorev.2025.106431_bib40","doi-asserted-by":"crossref","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neubiorev.2025.106431_bib41","doi-asserted-by":"crossref","unstructured":"Cozier G.E., Gardner M., Craft S., Skumlien M., Spicer J., Andrews R., Power A., Haines T., Bowman R., Manley A.E., Sunderland P., Sutcliffe O.B., Husbands S.M., Hines L., Taylor G., Freeman T.P., Scott J., Pudney C.R. Synthetic cannabinoids in e-cigarettes seized from English schools. Addiction. 2025 Jun 26. doi: 10.1111\/add.70110. Epub ahead of print. PMID: 40574414.","DOI":"10.1101\/2024.08.12.24311617"},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib42","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-024-06569-x","article-title":"A systematic review and meta-analysis of synthetic cathinone use and psychosis","volume":"241","author":"Daswani","year":"2024","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106431_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/jat\/bkw073","article-title":"Acute methiopropamine intoxication after \u201cSynthacaine\u201d consumption","author":"Daveluy","year":"2016","journal-title":"J. Anal. Toxicol."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/09638237.2012.682265","article-title":"e-Psychonauts: conducting research in online drug forum communities","volume":"21","author":"Davey","year":"2012","journal-title":"J. Ment. Health"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsat.2010.08.002","article-title":"A comparison of the symptoms and short-term clinical course in inpatients with substance-induced psychosis and primary psychosis","volume":"40","author":"Dawe","year":"2011","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.neubiorev.2025.106431_bib46","doi-asserted-by":"crossref","unstructured":"Di Petta, G., 2016. \u201cSynthetic psychosis\u201d by novel psychoactive substances: A psychopathological understanding of a clinical case. In An Experiential Approach to Psychopathology: What is it Like to Suffer From Mental Disorders? https:\/\/doi.org\/10.1007\/978-3-319-29945-7_9.","DOI":"10.1007\/978-3-319-29945-7_9"},{"key":"10.1016\/j.neubiorev.2025.106431_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8379562","article-title":"Severe psychosis, drug dependence, and hepatitis c related to slamming mephedrone","volume":"2016","author":"Dolengevich-Segal","year":"2016","journal-title":"Case Rep. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib48","doi-asserted-by":"crossref","DOI":"10.1007\/s13181-019-00734-x","article-title":"Severe toxicity to the new psychoactive substances 3-Hydroxyphencyclidine and N-Ethylhexedrone: an analytically confirmed case report","volume":"16","author":"Dunlop","year":"2020","journal-title":"J. Med. Toxicol."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib49","doi-asserted-by":"crossref","DOI":"10.3371\/CSRP.DUDE.031513","article-title":"Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report","volume":"8","author":"Durand","year":"2015","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/15563650.2018.1534241","article-title":"A novel synthetic cannabinoid (Cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it\u2019s not meningitis","volume":"57","author":"El Zahran","year":"2019","journal-title":"Clin. Toxicol."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib51","doi-asserted-by":"crossref","DOI":"10.1017\/S0790966700011915","article-title":"Whack induced psychosis: a case series","volume":"28","author":"El-Higaya","year":"2011","journal-title":"Ir. J. Psychol. Med."},{"key":"10.1016\/j.neubiorev.2025.106431_bib52","unstructured":"EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). (2019). EU Early Warning System operating guidelines."},{"key":"10.1016\/j.neubiorev.2025.106431_bib53","unstructured":"EMCDDA. (2022). EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances."},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2025.106431_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.drugalcdep.2011.01.012","article-title":"Synthetic cannabinoid JWH-018 and psychosis: an explorative study","volume":"117","author":"Every-Palmer","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neubiorev.2025.106431_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.694863","article-title":"Substance-Induced psychoses: an updated literature review","volume":"12","author":"Fiorentini","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/10550887.2014.950027","article-title":"NBOMe designer drug exposures reported to texas poison centers","volume":"33","author":"Forrester","year":"2014","journal-title":"J. Addict. Dis."},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2025.106431_bib57","article-title":"Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people","volume":"136","author":"Fraser","year":"2012","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib58","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/jat\/bkx080","article-title":"Toxicokinetics of the synthetic cathinone \u03b1-Pyrrolidinohexanophenone","volume":"42","author":"Fujita","year":"2018","journal-title":"J. Anal. Toxicol."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbw020","article-title":"Diagnostic stability of ICD\/DSM first episode psychosis diagnoses: Meta-analysis","volume":"42","author":"Fusar-Poli","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.neubiorev.2025.106431_bib60","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/head.12246","article-title":"CARE group. The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"53","author":"Gagnier","year":"2013","journal-title":"Headache"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/15563650.2015.1115056","article-title":"Case series: toxicity from 25B-NBOMe \u2013 a cluster of N-bomb cases","volume":"54","author":"Gee","year":"2016","journal-title":"Clin. Toxicol."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib62","article-title":"Molecular mechanisms of action of novel psychoactive substances (NPS). a new threat for young drug users with Forensic-Toxicological implications","volume":"11","author":"Giorgetti","year":"2021","journal-title":"Life (Basel Switz. )"},{"issue":"1377","key":"10.1016\/j.neubiorev.2025.106431_bib63","article-title":"Hospitalisation associated with use of the synthetic cannabinoid K2","volume":"126","author":"Glue","year":"2013","journal-title":"N. Z. Med. J."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib64","article-title":"Could spice drugs induce psychosis with abnormal movements similar to catatonia?","volume":"77","author":"Haro","year":"2014","journal-title":"Psychiatry (N. Y. )"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib65","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.psychres.2014.08.062","article-title":"Cognitive changes in patients with acute phase psychosis\u2014Effects of illicit drug use","volume":"220","author":"Helle","year":"2014","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib66","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings","volume":"108","author":"Hermanns-Clausen","year":"2013","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib67","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/15563650.2017.1393082","article-title":"Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA","volume":"56","author":"Hermanns-Clausen","year":"2018","journal-title":"Clin. Toxicol."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/15563650.2013.802795","article-title":"Severe clinical toxicity associated with analytically confirmed recreational use of 25I\u2013NBOMe: case series","volume":"51","author":"Hill","year":"2013","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106431_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2014.11.033","article-title":"Monitoring new psychoactive substances (NPS) in the Netherlands: data from the drug market and the poisons information centre","volume":"147","author":"Hondebrink","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2012.03.007","article-title":"A characterization of synthetic cannabinoid exposures reported to The National poison data system in 2010","volume":"60","author":"Hoyte","year":"2012","journal-title":"Ann. Emerg. Med."},{"issue":"10","key":"10.1016\/j.neubiorev.2025.106431_bib71","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2011.11010176","article-title":"Psychosis associated with synthetic cannabinoid agonists: a case series","volume":"168","author":"Hurst","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/0376-8716(91)90030-3","article-title":"Zipeprol is a newly abused antitussive with an opioid spectrum and hallucinogenic effects","volume":"27","author":"Janiri","year":"1991","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib73","doi-asserted-by":"crossref","DOI":"10.7205\/MILMED-D-10-00356","article-title":"Spice: a legal marijuana equivalent","volume":"176","author":"Johnson","year":"2011","journal-title":"Mil. Med."},{"issue":"21","key":"10.1016\/j.neubiorev.2025.106431_bib74","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.2169\/internalmedicine.53.2344","article-title":"A multicenter retrospective survey of poisoning after consumption of products containing synthetic chemicals in Japan","volume":"53","author":"Kamijo","year":"2014","journal-title":"Intern. Med."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib75","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/00952990.2016.1176177","article-title":"A multicenter retrospective survey of poisoning after consumption of products containing novel psychoactive substances from 2013 to 2014 in Japan","volume":"42","author":"Kamijo","year":"2016","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib76","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11055-019-00724-0","article-title":"A differential approach to the treatment of acute psychosis due to consumption of synthetic cannabinoids","volume":"49","author":"Kekelidze","year":"2019","journal-title":"Neurosci. Behav. Physiol."},{"issue":"8","key":"10.1016\/j.neubiorev.2025.106431_bib77","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-014-2802-4","article-title":"Emergence of new classes of recreational drugs - synthetic cannabinoids and cathinones","volume":"29","author":"Khullar","year":"2014","journal-title":"J. Gen. Intern. Med."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/pnp.331","article-title":"Transient psychotic episodes following recreational use of NRG-3","volume":"18","author":"Kihara","year":"2014","journal-title":"Prog. Neurol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib79","doi-asserted-by":"crossref","DOI":"10.1111\/j.1465-3362.2010.00196.x","article-title":"Long-term outcomes in methamphetamine psychosis patients after first hospitalisation","volume":"29","author":"Kittirattanapaiboon","year":"2010","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.neubiorev.2025.106431_bib80","doi-asserted-by":"crossref","DOI":"10.5455\/apd.260524","article-title":"Differences in sociodemographic characteristics, clinical features and serum liver function tests of Male cannabis and synthetic cannabinoid users","author":"Kotan","year":"2017","journal-title":"Anadolu Psikiyatr. Derg. 18(6"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib81","article-title":"Intensive care unit outcomes of the cases with cannabinoid intoxication","volume":"9","author":"Kuzucuo\u011flu","year":"2018","journal-title":"J. Med. Surg. Intensive Care Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib82","doi-asserted-by":"crossref","DOI":"10.1177\/0036933016649871","article-title":"The experience of an increase in the injection of ethylphenidate in lothian April 2014-March 2015","volume":"61","author":"Lafferty","year":"2016","journal-title":"Scott. Med. J."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib83","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/dta.2936","article-title":"Hair analysis can support the follow-up addiction care after acute new psychoactive substances intoxication: illustration by two cases","volume":"13","author":"Lagoutte-Renosi","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neubiorev.2025.106431_bib84","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2015.14166","article-title":"Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland","volume":"145","author":"Liakoni","year":"2015","journal-title":"Swiss Med. Wkly."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13049-017-0369-x","article-title":"Presentations to an urban emergency department in Bern, Switzerland associated with acute recreational drug toxicity","volume":"25","author":"Liakoni","year":"2017","journal-title":"Scand. J. Trauma Resusc. Emerg. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib86","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0000000000001649","article-title":"Comparison of psychiatric and clinical profiles between people who use synthetic cathinones and methamphetamine: a matched Case-Control study","volume":"43","author":"Lin","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib87","article-title":"NBOMe hallucinogenic drug exposures reported to the danish poison information centre","volume":"64","author":"Madsen","year":"2017","journal-title":"Dan. Med. J."},{"issue":"32","key":"10.1016\/j.neubiorev.2025.106431_bib88","doi-asserted-by":"crossref","DOI":"10.2174\/1381612827666211115170521","article-title":"Fourth generation of synthetic cannabinoid receptor agonists: a review on the latest insights","volume":"28","author":"Malaca","year":"2021","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib89","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/01676830.2020.1781199","article-title":"Synthetic cannabinoid induced ocular self-injury","volume":"40","author":"Malik","year":"2021","journal-title":"Orbit"},{"key":"10.1016\/j.neubiorev.2025.106431_bib90","first-page":"168","article-title":"Novel psychoactive substances: a toxicological challenge","volume":"187","author":"Martin S","year":"2019","journal-title":"Bull. R. Coll. Pathol."},{"issue":"27","key":"10.1016\/j.neubiorev.2025.106431_bib91","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2174\/1381612828666220623092853","article-title":"Atypical antipsychotic drugs in dual disorders: current evidence for clinical practice","volume":"28","author":"Martinotti","year":"2022","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/S1092852920001479","article-title":"Substance-related exogenous psychosis: a postmodern syndrome","volume":"26","author":"Martinotti","year":"2021","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib93","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/S1092852920001479","article-title":"Substance-related exogenous psychosis: a postmodern syndrome","volume":"26","author":"Martinotti","year":"2021","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib94","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/S1092852920001479","article-title":"Substance-related exogenous psychosis: a postmodern syndrome","volume":"26","author":"Martinotti","year":"2021","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib95","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/S1092852920001479","article-title":"Substance-related exogenous psychosis: a postmodern syndrome","volume":"26","author":"Martinotti","year":"2021","journal-title":"CNS Spectr."},{"issue":"13","key":"10.1016\/j.neubiorev.2025.106431_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18136944","article-title":"Club Drugs and Psychiatric Sequelae: An Issue of Vulnerability and Previous Psychiatric History","volume":"18","author":"Martinotti","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.neubiorev.2025.106431_bib97","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.addbeh.2019.02.009","article-title":"Synthetic cannabinoid use among college students","volume":"93","author":"Mathews","year":"2019","journal-title":"Addict. Behav."},{"issue":"12","key":"10.1016\/j.neubiorev.2025.106431_bib98","doi-asserted-by":"crossref","DOI":"10.1111\/pcn.12434","article-title":"Recent changes in the clinical features of patients with new psychoactive-substances-related disorders in Japan: comparison of the nationwide mental hospital surveys on Drug-related psychiatric disorders undertaken in 2012 and 2014","volume":"70","author":"Matsumoto","year":"2016","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib99","doi-asserted-by":"crossref","DOI":"10.1111\/j.1440-1819.2008.01764.x","article-title":"2C-T-4 intoxication: acute psychosis caused by a designer drug","volume":"62","author":"Miyajima","year":"2008","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1080\/02791072.2019.1578444","article-title":"Dorsolateral prefrontal cortex impairment in Methoxetamine-Induced psychosis: an 18 F-FDG PET\/CT case study","volume":"51","author":"Moccia","year":"2019","journal-title":"J. Psychoact. Drugs"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s13181-017-0605-9","article-title":"Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: a ToxIC database study","volume":"13","author":"Monte","year":"2017","journal-title":"J. Med. Toxicol."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib102","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/schbul\/sbae061","article-title":"Towards the DSM-6: results of a survey of experts on the reintroduction of First-Rank symptoms as core criteria of schizophrenia and on redefining hallucinations","volume":"50","author":"Moritz","year":"2024","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.neubiorev.2025.106431_bib103","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.2174\/1570159X21666221017085612","article-title":"Ibogaine\/Noribogaine in the treatment of substance use disorders: a systematic review of the current literature","volume":"21","author":"Mosca","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neubiorev.2025.106431_bib104","series-title":"In Psychosis, Trauma and Dissociation","first-page":"55","article-title":"The role of dissociation in the historical concept of schizophrenia","author":"Moskowitz","year":"2018"},{"issue":"s 1\u20133","key":"10.1016\/j.neubiorev.2025.106431_bib105","article-title":"The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes","volume":"118","author":"M\u00fcller","year":"2010","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib106","doi-asserted-by":"crossref","DOI":"10.3109\/15563650.2011.647992","article-title":"Ivory wave\u2019 toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning","volume":"50","author":"Murray","year":"2012","journal-title":"Clin. Toxicol."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib107","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/schbul\/sbz102","article-title":"Transition of Substance-Induced, brief, and atypical psychoses to schizophrenia: a systematic review and Meta-analysis","volume":"46","author":"Murrie","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.neubiorev.2025.106431_bib108","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamapsychiatry.2023.3582","article-title":"Transition to schizophrenia spectrum disorder following emergency department visits due to substance use with and without psychosis","volume":"80","author":"Myran","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106431_bib109","series-title":"Synthetic cannabinoids (K2\/Spice)","author":"NIDA (National Institute on Drug Abuse)","year":"2024"},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2012.0004","article-title":"Synthetic Cannabinoid-Induced psychosis: two adolescent cases","volume":"22","author":"Oluwabusi","year":"2012","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106431_bib111","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5350\/DAJPN2016290410","article-title":"Capgras syndrome after use of synthetic cannabinoids: an adolescent case","author":"Ozer","year":"2016","journal-title":"Dusunen Adam J. Psychiatry Neurol. Sci."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib112","article-title":"Sociodemographic and clinical features of young adult males using synthetic cannabinoid. In klinik psikiyatri dergisi","volume":"21","author":"\u00d6znur","year":"2018"},{"key":"10.1016\/j.neubiorev.2025.106431_bib113","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib114","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hup.2312","article-title":"Spiceophrenia\u201d: a systematic overview of \u201cSpice\u201d-related psychopathological issues and a case report","volume":"28","author":"Papanti","year":"2013","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib115","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hup.2312","article-title":"Spiceophrenia\u201d: a systematic overview of \u201cSpice\u201d-related psychopathological issues and a case report","volume":"28","author":"Papanti","year":"2013","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.neubiorev.2025.106431_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00206","article-title":"Acute pharmacological effects of 2C-B in humans: an observational study","volume":"9","author":"Papaseit","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106431_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00233","article-title":"Acute effects of 2C-E in humans: an observational study","volume":"11","author":"Papaseit","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106431_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.110721","article-title":"Alpha-Pyrrolidinopentiothiophenone (\u03b1-PVT): a forensic case study including plasma concentrations","volume":"321","author":"Paul","year":"2021","journal-title":"Forensic Sci. Int."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib119","doi-asserted-by":"crossref","DOI":"10.1111\/j.1521-0391.2012.00222.x","article-title":"Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient","volume":"21","author":"Peglow","year":"2012","journal-title":"Am. J. Addict."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib120","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291720003293","article-title":"Schneider\u2019s first-rank symptoms have neither diagnostic value for schizophrenia nor higher clinical validity than other delusions and hallucinations in psychotic disorders","volume":"53","author":"Peralta","year":"2023","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib121","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1515\/ijamh-2013-0505","article-title":"Treatment of refractory substance-induced psychosis in adolescent males with a genetic predisposition to mental illness","volume":"26","author":"Rahmani","year":"2014","journal-title":"Int. J. Adolesc. Med. Health"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib122","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/10550887.2021.1945398","article-title":"Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report","volume":"40","author":"Ricci","year":"2022","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neubiorev.2025.106431_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/7257489","article-title":"First-Episode of synthetic Cannabinoid-Induced psychosis in a young adult, successfully managed with hospitalization and risperidone","volume":"2016","author":"Roberto","year":"2016","journal-title":"Case Rep. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib124","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/15563650.2016.1271424","article-title":"11 analytically confirmed cases of mexedrone use among polydrug users","volume":"55","author":"Roberts","year":"2017","journal-title":"Clin. Toxicol."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/15563650.2020.1828592","article-title":"Synthetic cannabis: adverse events reported to the New Zealand pharmacovigilance centre","volume":"59","author":"Robson","year":"2021","journal-title":"Clin. Toxicol."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib126","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1176\/appi.ajp.22010076","article-title":"Transition from Substance-Induced psychosis to schizophrenia spectrum disorder or bipolar disorder","volume":"180","author":"Rognli","year":"2023","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib127","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/15563650.2017.1301463","article-title":"Synthetic cathinones in Southern Germany \u2013 characteristics of users, substance-patterns, co-ingestions, and complications","volume":"55","author":"Romanek","year":"2017","journal-title":"Clin. Toxicol."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib128","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3109\/15563650.2013.772191","article-title":"A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug","volume":"51","author":"Rose","year":"2013","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106431_bib129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00413244","article-title":"THE EFFECT OF N,N-DIMETHYLTRYPTAMINE IN HUMAN SUBJECTS TOLERANT TO LYSERGIC ACID DIETHYLAMIDE","volume":"5","author":"ROSENBERG","year":"1964","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neubiorev.2025.106431_bib130","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.10329","article-title":"Synthetic cannabinoids and its association with persistent negative symptoms of schizophrenia","author":"Satodiya","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.neubiorev.2025.106431_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112295","article-title":"A retrospective analysis of the \u201cNeverending Trip\u201d after administration of a potent full agonist of 5-HT2A receptor \u2013 25I-NBOMe","volume":"146","author":"Schetz","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neubiorev.2025.106431_bib132","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.coph.2021.02.008","article-title":"The e-psychonaut drugs\u2019 psychopharmacology","volume":"57","author":"Schifano","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib133","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20174","article-title":"Novel psychoactive substances of interest for psychiatry","volume":"14","author":"Schifano","year":"2015","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib134","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7555\/JBR.32.20180023","article-title":"Psychotic due to bath salts and methamphetamines: emergency cesarean section under general anesthesia","volume":"32","author":"Schloemerkemper","year":"2018","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.neubiorev.2025.106431_bib135","author":"Schneider","year":"1959","journal-title":"Clin. Psychopathol."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib136","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/15563650.2011.584316","article-title":"Three cases of \u201cspice\u201d exposure","volume":"49","author":"Simmons","year":"2011","journal-title":"Clin. Toxicol."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib137","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/02791072.2018.1447172","article-title":"Marvin, the paranoid Android\u201d: the case of an Alpha-PVP user in the expanding galaxy of NPS","volume":"50","author":"Simonato","year":"2018","journal-title":"J. Psychoact. Drugs"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib138","article-title":"Psychotic disorders in patients who use synthetic cannabinoids","volume":"25","author":"Skryabin","year":"2019","journal-title":"J. Psychiatr. Pract."},{"issue":"3\u20134","key":"10.1016\/j.neubiorev.2025.106431_bib139","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/10550887.2019.1627635","article-title":"Clinical characteristics of synthetic cannabinoid-induced psychotic disorders: a single-center analysis of hospitalized patients","volume":"37","author":"Skryabin","year":"2018","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neubiorev.2025.106431_bib140","article-title":"First rank symptoms for schizophrenia","author":"Soares-Weiser","year":"2015","journal-title":"Cochrane Database Syst. Rev. (Vol. 2017 Issue 6)."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib141","article-title":"Psychotic disorder associated with synthetic cannabinoid receptor agonists: a case report","volume":"27","author":"S\u00f6nmez","year":"2016","journal-title":"Turk. Psikiyatr. Derg."},{"key":"10.1016\/j.neubiorev.2025.106431_bib142","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.neubiorev.2025.106431_bib143","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jflm.2014.04.007","article-title":"Novel psychoactive substance intoxication resulting in attempted murder","volume":"25","author":"Stevenson","year":"2014","journal-title":"J. Forensic Leg. Med."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib144","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jat\/bkw108","article-title":"Mistaking 2C-P for 2C-B: what a difference a letter makes","volume":"41","author":"Stoller","year":"2017","journal-title":"J. Anal. Toxicol."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib145","article-title":"Psychiatric symptoms and synthetic cannabinoid use: information for clinicians","volume":"7","author":"Sweet","year":"2017","journal-title":"Ment. Health Clin."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib146","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.1966.01730150096014","article-title":"Psychological effects and metabolism of N,N-diethyltryptamine in man","volume":"15","author":"Szara","year":"1966","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2025.106431_bib147","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00787-012-0282-9","article-title":"Drug-induced acute psychosis in an adolescent first-time user of 4-HO-MET","volume":"21","author":"T\u00e4ljemark","year":"2012","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/S0376-8716(01)00146-6","article-title":"The subjective effects of MDMA and mCPP in moderate MDMA users","volume":"65","author":"Tancer","year":"2001","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib149","doi-asserted-by":"crossref","DOI":"10.1089\/can.2018.0047","article-title":"Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: responders versus nonresponders","volume":"4","author":"Theunissen","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"issue":"5","key":"10.1016\/j.neubiorev.2025.106431_bib150","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-021-05768-0","article-title":"Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis","volume":"239","author":"Theunissen","year":"2022","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.neubiorev.2025.106431_bib151","doi-asserted-by":"crossref","DOI":"10.1177\/0269881109102608","article-title":"Randomised double-blind, placebo-controlled trial of the effects of the \u2018party pills\u2019 BZP\/TFMPP alone and in combination with alcohol","volume":"24","author":"Thompson","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib152","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0b013e3182619004","article-title":"Internet highs-seizures after consumption of synthetic cannabinoids purchased online","volume":"6","author":"Tofighi","year":"2012","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib153","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2011.179507","article-title":"Violent behavior and hallucination in a 32-year-old patient","volume":"59","author":"Truscott","year":"2013","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.neubiorev.2025.106431_bib154","article-title":"Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong","volume":"22","author":"Tung","year":"2012","journal-title":"East Asian Arch. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106431_bib155","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1503\/cmaj.170361","article-title":"Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with parkinson disease","volume":"190","author":"Udow","year":"2018","journal-title":"Can. Med. Assoc. J."},{"issue":"7","key":"10.1016\/j.neubiorev.2025.106431_bib156","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/15563650.2016.1166508","article-title":"Clinical characteristics of \u03b1-pyrrolidinovalerophenone (\u03b1-PVP) poisoning","volume":"54","author":"Umebachi","year":"2016","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106431_bib157","unstructured":"UNODC (United Nations Office on Drugs and Crime). (2020). World Drug Report 2020."},{"key":"10.1016\/j.neubiorev.2025.106431_bib158","unstructured":"UNODC (United Nations Office on Drugs and Crime). (2024). New psychoactive substances: Data visualisations."},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib159","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0269881114565142","article-title":"The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects","volume":"29","author":"van Amsterdam","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.neubiorev.2025.106431_bib160","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00127-014-0894-0","article-title":"Childhood maltreatment, adult attachment and psychotic symptomatology: a study in patients, siblings and controls","volume":"49","author":"van Dam","year":"2014","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib161","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10826084.2018.1521430","article-title":"A systematic review of the symptom profile and course of Methamphetamine-Associated psychosis","volume":"54","author":"Voce","year":"2019","journal-title":"Subst. Use Misuse"},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib162","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/15563650.2016.1171329","article-title":"Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom national poisons information service","volume":"54","author":"Waugh","year":"2016","journal-title":"Clin. Toxicol."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib163","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000479554","article-title":"Synthetic cannabinoid use in a psychiatric patient population: a pilot study","volume":"23","author":"Welter","year":"2017","journal-title":"Eur. Addict. Res."},{"issue":"7","key":"10.1016\/j.neubiorev.2025.106431_bib164","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/15563650.2018.1538519","article-title":"Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine. A report from the identification of novel psychoactive substances (IONA) study","volume":"57","author":"White","year":"2019","journal-title":"Clin. Toxicol."},{"issue":"6","key":"10.1016\/j.neubiorev.2025.106431_bib165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/10673220802564186","article-title":"Postmodernity and mental health","volume":"16","author":"Whitley","year":"2008","journal-title":"Harv. Rev. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib166","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.2012.704592","article-title":"Psychoactive properties of alpha-methyltryptamine: analysis from self reports of users","volume":"44","author":"Wilcox","year":"2012","journal-title":"J. Psychoact. Drugs"},{"issue":"3","key":"10.1016\/j.neubiorev.2025.106431_bib167","doi-asserted-by":"crossref","DOI":"10.1080\/14659890701288945","article-title":"The prevalence of use, dependency and harms of legal \u2018party pills\u2019 containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand","volume":"12","author":"Wilkins","year":"2007","journal-title":"J. Subst. Use"},{"key":"10.1016\/j.neubiorev.2025.106431_bib168","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2307\/4585762","article-title":"Studies on marihuana and pyrahexyl compound","volume":"61","author":"WILLIAMS","year":"1846","journal-title":"Public Health Rep."},{"key":"10.1016\/j.neubiorev.2025.106431_bib169","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.schres.2017.11.001","article-title":"Clinical characteristics of primary psychotic disorders with concurrent substance abuse and substance-induced psychotic disorders: a systematic review","volume":"197","author":"Wilson","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neubiorev.2025.106431_bib170","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3894749","article-title":"Delirium and High Creatine Kinase and Myoglobin Levels Related to Synthetic Cannabinoid Withdrawal","author":"Yazici","year":"2017","journal-title":"Case Rep. Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2025.106431_bib171","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jat\/bkx009","article-title":"Two cases of Non-fatal intoxication with a novel street hallucinogen: 3-Methoxy-Phencyclidine","volume":"41","author":"Zidkova","year":"2017","journal-title":"J. Anal. Toxicol."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425004324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425004324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:57:47Z","timestamp":1786971467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763425004324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":171,"alternative-id":["S0149763425004324"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106431","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel psychoactive substances (NPS) as a risk factor for psychosis: A systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106431"}}